Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Idiopathic Inflammatory Myopathy (IIM)
Sponsor: Xencor, Inc.
Summary
The purpose of this study is to determine the safety and tolerability of XmAb657 in healthy participants and participants with IIM. Participants will be given XmAb657 subcutaneously (SC) by injection under the skin.
Official title: A Phase 1, First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of XmAb657 in Healthy Participants and in Participants With Idiopathic Inflammatory Myopathy
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
27
Start Date
2026-02
Completion Date
2027-02
Last Updated
2025-12-16
Healthy Volunteers
Yes
Interventions
XmAb13676
Biological
Locations (1)
Xencor Investigative Site
Melbourne, Australia